title: Reversal of tacrolimus-related hypertrophic cardiomyopathy after conversion to rapamycin in a pediatric liver transplant recipient.
abstract: Tacrolimus (Tac)-related hypertrophic cardiomyopathy (HCM) has been reported to be an unusual but serious complication affecting pediatric patients after solid organ transplantation. Herein, we present a case of young liver transplant recipient with Tac-induced HCM, treated by discontinuation of Tac followed by conversion to rapamycin (Rap). Our case report points out the potential but rather low risk of HCM during Tac immunosuppression in pediatric liver transplants and demonstrates that replacement of calcineurin inhibitors with mammalian target of Rap (mTOR) inhibitors may be an efficacious therapeutic tool to effect regression of established cardiac hypertrophy.
authors: Department of Cardiology, The Children's Memorial Health Institute, Warsaw, Poland. turskakmiec@op.pl
authors: Anna
authors: A
authors: Turska-Kmieć
authors: Irena
authors: I
authors: Jankowska
authors: Joanna
authors: J
authors: Pawłowska
authors: Piotr
authors: P
authors: Kaliciński
authors: Wanda
authors: W
authors: Kawalec
authors: Małgorzata
authors: M
authors: Tomyn
authors: Małgorzata
authors: M
authors: Markiewicz
authors: Joanna
authors: J
authors: Teisseyre
authors: Piotr
authors: P
authors: Czubkowski
authors: Joanna
authors: J
authors: Rekawek
authors: Jerzy
authors: J
authors: Socha
mesh_terms: D002312:Cardiomyopathy, Hypertrophic / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D007223:Infant; D016031:Liver Transplantation; D020123:Sirolimus / Q000627:therapeutic use*; D016559:Tacrolimus / Q000009:adverse effects*; D014463:Ultrasonography
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus; D016559:Tacrolimus